Emergent BioSolutions, Inc. (EBS)
6.46
+0.24
(+3.86%)
USD |
NYSE |
Sep 02, 16:00
6.42
-0.04
(-0.62%)
Pre-Market: 06:51
Emergent BioSolutions Research and Development Expense (TTM) : 45.30M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 45.30M |
| March 31, 2026 | 49.10M |
| December 31, 2025 | 53.80M |
| September 30, 2025 | 50.90M |
| June 30, 2025 | 50.60M |
| March 31, 2025 | 64.90M |
| December 31, 2024 | 64.70M |
| September 30, 2024 | 84.70M |
| June 30, 2024 | 85.90M |
| March 31, 2024 | 84.20M |
| December 31, 2023 | 112.60M |
| September 30, 2023 | 141.00M |
| June 30, 2023 | 168.20M |
| March 31, 2023 | 191.10M |
| December 31, 2022 | 193.60M |
| September 30, 2022 | 219.00M |
| June 30, 2022 | 226.10M |
| March 31, 2022 | 225.90M |
| December 31, 2021 | 231.40M |
| September 30, 2021 | 207.90M |
| June 30, 2021 | 243.60M |
| March 31, 2021 | 243.20M |
| December 31, 2020 | 234.50M |
| September 30, 2020 | 237.80M |
| June 30, 2020 | 206.80M |
| Date | Value |
|---|---|
| March 31, 2020 | 222.80M |
| December 31, 2019 | 226.20M |
| September 30, 2019 | 215.40M |
| June 30, 2019 | 199.01M |
| March 31, 2019 | 159.85M |
| December 31, 2018 | 142.80M |
| September 30, 2018 | 119.30M |
| June 30, 2018 | 104.95M |
| March 31, 2018 | 105.96M |
| December 31, 2017 | 97.38M |
| September 30, 2017 | 96.00M |
| June 30, 2017 | 100.53M |
| March 31, 2017 | 102.67M |
| December 31, 2016 | 108.29M |
| September 30, 2016 | 106.50M |
| June 30, 2016 | 109.03M |
| March 31, 2016 | 122.08M |
| December 31, 2015 | 134.68M |
| September 30, 2015 | 148.32M |
| June 30, 2015 | 162.82M |
| March 31, 2015 | 159.28M |
| December 31, 2014 | 150.83M |
| September 30, 2014 | 141.86M |
| June 30, 2014 | 126.59M |
| March 31, 2014 | 119.46M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Exelixis, Inc. | 824.32M |
| Capricor Therapeutics, Inc. | 98.66M |
| ADMA Biologics, Inc. | 11.52M |
| Akebia Therapeutics, Inc. | 68.91M |
| Arcutis Biotherapeutics, Inc. | 91.04M |